Feb 14 (Reuters) - Hikma Pharmaceuticals Plc said itexpects a 23 percent growth in full-year revenue, up from itsprior forecast of about 20 percent, benefiting from strongperformance in its injectables and generics businesses towardsthe end of 2013.
The company, which has grown over the past year on the backof a shortage of doxycycline in the United States, also raisedits full-year generics revenue forecast to 270 million pounds($449.18 million) as sales of the antibiotic continued to rise.
The drugmaker has raised its full-year revenue forecast fourtimes this year and said in November that it expected revenuefrom its generics unit to be about $260 million.
However, Hikma said that it expects revenue from itsgenerics business to be lower in 2014 due to increasedcompetition in the U.S. doxycycline market.
Hikma said its global injectables business performed well,with revenue growth of about 14 percent.
"We are confident that our Injectables business willcontinue to deliver strong revenue growth and an adjustedoperating margin above 30 percent in 2014," the company said ina statement.
Shares in the company closed at 1244 pence on Thursday onthe London Stock Exchange.
Hikma Pharmaceuticals (HIK)
